Here is the list of Top Best Pharma Company in India based on Market Capitalization in India
- Sun Pharmaceuticals Industries Ltd
- Dr. Reddy’s Laboratories Ltd
- Divi’s Laboratories Ltd
- Cipla Ltd
- Biocon Ltd
- Aurobindo Pharma Ltd
- Lupin Ltd
- Torrent Pharmaceuticals Ltd
- Cadila Healthcare Ltd
Overview of Pharma Industry
Global pharmaceutical industry
Global spending on medicines crossed US$ 1.2 Trillion in 2018; and is projected to grow at a compound annual growth rate (CAGR) of 3-6% in the next five years, reaching over US$ 1.5 Trillion by 2023. Growth in the global pharmaceutical market will continue to be led by the US and pharmerging markets.
Indian pharmaceutical market
India enjoys a key position in the global pharmaceutical industry. The country is the world’s largest supplier of generics, accounting for 20% of global exports. It supplies over 50% of global demand for various vaccines and 40% of the demand for generic products in the US. The domestic pharmaceutical market contributes to ~2% of the global industry in value and ~10% in volume terms.
List of Top Best Pharma Company In India
#1. Sun Pharmaceuticals Industries Ltd
Sun Pharmaceuticals Industries Ltd is the No.1 Pharma company listed in India with a market cap of 114,412 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1983 |
| Founder | Dilip Shanghvi |
| Headquarters | Goregaon, Mumbai |
| Chairman | Israel Makov |
| CEO & MD | Dilip S Shanghvi |
Sun Pharmaceutical Industries Limited including its subsidiaries and associates (Sun Pharma) is the fourth largest global specialty generic company that is ranked No. 1 in India and No. 8 in the US.
It is the largest Indian pharmaceutical company in the US and among the leading Indian pharmaceutical companies in emerging markets.
BUSINESS SEGMENTS
US business
- 8th largest generics company in the US with a strong pipeline (118 ANDAs and 8 NDAs awaiting approval).
- Presence in generics, specialty and branded segments with 450+ approved products.
- FY19 sales: `106,713 Million.
Indian branded generics business
- Ranked No. 1 across 11 classes of doctors.
- Leading position in high growth chronic therapies.
- Specialises in technically complex products.
- FY19 sales: `73,483 Million.
Emerging markets
- Presence in ~100 countries across Africa, Americas, Asia and Eastern and Central Europe.
- Key focus geographies include Brazil, Mexico, Russia, Romania, South Africa, and complementary and affiliated markets.
- FY19 sales: `53,624 Million.
Rest of world
- Presence across majority of markets in Western Europe, Canada, Japan, Australia, and New Zealand.
- Products include differentiated offerings for hospitals, injectables and generics for retail market.
- Portfolio of long-listed products servicing the Japanese market.
- FY19 sales: `34,554 Million
Global consumer healthcare business
- Among the top 10 consumer healthcare companies in India.
- Operates in 20+ countries.
API business
- Backward integration provides cost competitiveness and supply reliability.
- Portfolio of 300+ approved DMF/CEP products.
Current Year Fiancial Data
- Market Cap: 114,412 Cr.
- Current Price: 476.85
- 52 weeks High / Low 512.70 / 312.00
- Book Value: 188.65
- Stock P/E: 28.69
- Dividend Yield: 0.63 %
- ROCE: 11.19 %
- ROE: 9.19 %
- Sales Growth (3Yrs): 0.67 %
Bonus Share Issue History
Bonus History (Sun Pharmaceutical Industries)
| Date | Bonus Ratio |
|---|---|
| 28-05-2013 | 1:1 |
| 21-04-2004 | 1:1 |
| 09-02-2000 | 2:1 |
Sun Pharmaceutical Industries Limited Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 4,007 | 32,838 | 23.41% |
| Profit | 1,351 | 3,765 | 10.79% |
| Share Price | 157.82 | 476.85 | 11.69% |
#2. Dr Reddy’s Laboratories Ltd
Dr. Reddy’s Laboratories Ltd is the 2nd largest pharma company in India with a market cap of 65,187 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1984 |
| Founder | Kallam Anji Reddy |
| Headquarters | Hyderabad |
| Chairman | K SATISH REDDY |
| MD | G V PRASAD |
BUSINESS SEGMENTS
GLOBAL GENERICS (GG) :
Global Generics (GG), which covers branded and unbranded prescription medicine as well as over-the-counter (OTC) pharmaceutical products. It also includes the biosimilars business.
Revenue : 123 billion
PHARMACEUTICAL SERVICES AND ACTIVE INGREDIENTS (PSAI)
Pharmaceutical Services & Active Ingredients (PSAI), which accounts for Active Pharmaceutical Ingredients (APIs) and Custom Pharmaceutical Services (CPS).
Revenue : 24 billion
PROPRIETARY PRODUCTS & OTHERS
Proprietary Products (PP), which mainly comprises the differentiated formulations business, focusing on certain key medical needs.
Revenue : 7 billion
REVENUE MIX BY SEGMENTS
DRL, currently, has eight API-manufacturing facilities, which are USFDA approved (six in India, one in Mexico and one in Mirfield, United Kingdom ) and 13 formulations manufacturing facilities (including the ones through JVs). In addition, it has one biologics facility in India and several technology developments and R&D centers in India and across the globe.
Current Year Fiancial Data
- Market Cap: 65,187 Cr.
- Current Price: 3,921
- 52 weeks High / Low 4190.00 / 2351.20
- Book Value: 938.37
- Stock P/E: 32.18
- Dividend Yield: 0.64 %
- ROCE: 12.42 %
- ROE: 13.61 %
- Sales Growth (3Yrs): -0.26 %
Bonus Share Issue History
Bonus History (Dr Reddys Laboratories)
| Date | Bonus Ratio |
|---|---|
| 31-05-2006 | 1:1 |
| 24-03-1994 | 2:1 |
| 30-09-1992 | 1:1 |
| 03-12-1991 | 1:2 |
Dr. Reddy’s Laboratories Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 7,031 | 17,517 | 9.56% |
| Profit | 352 | 2,026 | 19.13% |
| Share Price | 1153 | 3921 | 13.02% |
#3. Divi’s Laboratories Ltd
Divi’s Laboratories Ltd is the 3rd largest pharma company in India with a market cap of 58,150 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1990 |
| Founder | Murali Divi |
| Chairman & Managing Director | Dr. Murali. K. Divi |
Divi’s is leading manufacturer of active pharma ingredients (API) with predominance in exports; and exports to advanced markets in Europe and America constitute about 73% of its revenue.
Company is recognized as a reliable supplier of generic APIs, a trustworthy
custom manufacturer to big pharma and is among the top API manufacturers worldwide.
BUSINESS SEGMENTS
The company’s product portfolio comprises of two broad categories
- Generic APIs (Active Pharma Ingredients) and Nutraceuticals
- Custom Synthesis of APIs, intermediates, and specialty ingredients for innovator pharma giants.
The Company operates predominantly in export markets and has
a broad product portfolio under generics and custom synthesis. Among Divi’s well-distributed product range, some of the components of the business are
DLL owns four manufacturing units and three R&D Centers spread across Andhra Pradesh and Telangana.
Current Year Fiancial Data
- Market Cap: 58,150 Cr.
- Current Price: 2,190
- 52 weeks High / Low 2537.95 / 1466.00
- Book Value: 275.36
- Stock P/E: 42.24
- Dividend Yield: 0.73 %
- ROCE: 28.51 %
- ROE: 21.01 %
- Sales Growth (3Yrs): 9.41 %
Bonus Share Issue History
Bonus History (Divis Laboratories)
| Date | Bonus Ratio |
|---|---|
| 08-08-2015 | 1:1 |
| 06-06-2009 | 1:1 |
Divi’s Laboratories Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 942 | 5,394 | 19.07% |
| Profit | 340 | 1,377 | 15.01% |
| Share Price | 323.77 | 2190 | 21.07% |
#4. Cipla Ltd
Cipla Ltd is the 4th largest pharma company in India with a market cap of 51,505 Cr. in 2020.
| Industry | Pharmaceuticals |
| Founded | 1935 |
| Founder | Khwaja Abdul Hamied |
| Chairman | Dr. Y. K. Hamied |
| MD | Umang Vohra |
Cipla Ltd is one of the leading Pharmaceutical companies in India, and third largest in South Africa (by market share), and has a widespread presence across the globe through various subsidiaries/associates as reflected in 62% of consolidated net revenue being contributed through sales outside India in FY19.
- The company has a diverse range of more than 1,500 products (with more than 50 dosage forms).
- The company has 46 manufacturing facilities with a presence in over 80 markets.
The company has a diversified product portfolio and leadership in domestic segments including in respiratory, anti-infective, cardiac, gynecology, and gastrointestinal therapies; considerable market share in niche segments like HIV/AIDS and respiratory in countries like South Africa and India respectively.
Current Year Fiancial Data
- Market Cap: 51,505 Cr.
- Current Price: 638.80
- 52 weeks High / Low 696.00 / 355.30
- Book Value: 195.50
- Stock P/E: 33.30
- Dividend Yield: 0.47 %
- ROCE: 10.94 %
- ROE: 9.62 %
- Sales Growth (3Yrs): 5.87 %
Bonus Share Issue History
Bonus History (Cipla)
| Date | Bonus Ratio |
|---|---|
| 11-02-2006 | 3:2 |
| 07-10-1999 | 2:1 |
| 24-03-1994 | 5:1 |
| 30-09-1992 | 1:1 |
| 11-10-1988 | 1:1 |
| 23-08-1986 | 1:1 |
| 23-08-1980 | 1:1 |
Cipla Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 5,360 | 17,132 | 12.32% |
| Profit | 1,083 | 1,547 | 3.63% |
| Share Price | 318 | 638 | 7.21% |
#5. Biocon Ltd
Biocon Ltd is the 5th largest pharma company in India with a market cap of 47,472 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1978 |
| Founder | Kiran Mazumdar-Shaw |
| CEO & MD | Siddharth Mittal |
Biocon, founded in 1978, is India’s leading biopharma company. It is fully integrated and delivers biopharma solutions, ranging from discovery to development and commercialization.
BUSINESS SEGMENTS
The company has a relatively diversified product portfolio, lending stability to revenues.
Small molecules and research services are relatively larger verticals for the company contributing to 31% and 30% of revenues respectively in FY2020. Biologics contributed to 29% of FY2020 revenues for Biocon, while its branded formulations business contributed to 8% of revenues.
In terms of geographies, the company is fairly diversified with about 22% of revenues from Domestic and 78% from international market.
Current Year Fiancial Data
- Market Cap: 47,472 Cr.
- Current Price: 395.60
- 52 weeks High / Low 410.45 / 211.05
- Book Value: 62.81
- Stock P/E: 155.83
- Dividend Yield: 0.13 %
- ROCE: 5.30 %
- ROE: 4.16 %
- Sales Growth (3Yrs): -8.41 %
Bonus Share Issue History
Bonus History (Biocon)
| Date | Bonus Ratio |
|---|---|
| 25-04-2019 | 1:1 |
| 27-04-2017 | 2:1 |
| 22-04-2008 | 1:1 |
Biocon Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 1,163 | 1,988 | 5.51% |
| Profit | 248 | 441 | 5.93% |
| Share Price | 45.93 | 395.60 | 24.03% |
#6. Aurobindo Pharma Ltd
Aurobindo Pharma Ltd is the 6th largest pharma company in India with a market cap of 45,577 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1986 |
| Founder | P.V. Ramprasad Reddy, K.Nityananda Reddy |
| MD | N. Govindarajan |
APL, headquartered in Hyderabad, is a vertically-integrated pharmaceutical formulations manufacturer.
- Aurobindo is the tenth-largest generic company globally based on revenues.
- It is also the second-largest generics company in the US in terms of prescriptions dispensed for the 12 months ending March 2019 (Source: IQVIA), and one of the leading players in Canada and Portugal.
- The company exports to over 155 countries and derives around 90% of its revenues from international sales.
BUSINESS SEGMENTS
The company mainly operate in two major segments
#1. FORMULATIONS BUSINESS:
- The formulations business contributes 82.6% to the Company’s revenues.
- The Company manufactures these products from 16 manufacturing facilities and markets them in over 155 countries including developed markets such as the US and Europe
Sub-segments
- US formulations
- EU formulations
- Growth markets formulations
- ARV formulations
#2. API Business
Aurobindo manufactures and markets Active Pharmaceutical Ingredients (API) across the globe, apart from using them for internal consumption. It markets Betalactum and non-Betalactum manufactured at its 11 API and intermediate facilities.
It has 16 formulation manufacturing facilities (three in the US, one in Brazil and one in Portugal) and 11 active pharmaceutical ingredients manufacturing facilities. The facilities have regulatory approvals from major international agencies.
Current Year Fiancial Data
- Market Cap: 45,577 Cr.
- Current Price: 777.85
- 52 weeks High / Low 819.75 / 281.15
- Book Value: 286.90
- Stock P/E: 15.99
- Dividend Yield: 0.39 %
- ROCE: 18.45 %
- ROE: 19.01 %
- Sales Growth (3Yrs): 12.41 %
Bonus Share Issue History
Bonus History (Aurobindo Pharma)
| Date | Bonus Ratio |
|---|---|
| 28-05-2015 | 1:1 |
| 22-02-2000 | 1:1 |
| 08-10-1998 | 1:1 |
Aurobindo Pharma Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 3,515 | 23,098 | 20.72% |
| Profit | 563 | 2,831 | 17.53% |
| Share Price | 94.93 | 777.85 | 23.41% |
#7. Lupin Ltd
Lupin Ltd is the 7th largest pharma company in India with a market cap of 40,780 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1968 |
| Founder | Desh Bandhu Gupta |
| CEO | Vinita D. Gupta |
| MD | Mr. Nilesh Deshbandhu Gupta |
Lupin is a leading global pharmaceutical company headquartered in Mumbai (Maharashtra), India.
It is a significant player in key therapy areas such as cardiovascular, anti-TB (world leader), anti-asthma, anti-diabetic, anti-infective, gastro-intestinal (GI), central nervous system (CNS), and gynecology
BUSINESS SEGMENTS
The company mainly operate in 4 segments
#1. Generics:
Generics business manufactures and markets branded and unbranded generics products across markets.
#2. Complex Generics :
Over the past few years, the company has made strategic investments in capabilities and infrastructure to create development expertise across complex generics (in particular, across long-acting injectables, inhalation, and biosimilars).
#3. Specialty
#4. API Business :
In addition to these three segments, It has other activities, primarily the sale of Active Pharmaceutical Ingredients (API) to third parties in more than 50 countries worldwide and institutional sales of important anti-TB products.
Current Year Fiancial Data
- Market Cap: 40,780 Cr.
- Current Price: 900.05
- 52 weeks High / Low 956.00 / 504.75
- Book Value: 276.69
- Stock P/E:
- Dividend Yield: 0.56 %
- ROCE: 9.97 %
- ROE: 5.38 %
- Sales Growth (3Yrs): 5.46 %
Bonus Share Issue History
Bonus History (Lupin)
| Date | Bonus Ratio |
|---|---|
| 17-05-2006 | 1:1 |
Lupin Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 4,774 | 15,916 | 12.80% |
| Profit | 682 | -269 | – |
| Share Price | 304.17 | 900.05 | 11.46% |
#8. Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Ltd is the 8th largest pharma company in India with a market cap of 40,532 Cr. in 2020
| Industry | Pharmaceuticals |
| Founded | 1959 |
| Chairman | Shri Sudhir Mehta |
Torrent Pharma Ltd is one of the front-runners in the Indian pharmaceutical industry having a presence in Domestic as well as international markets.
The company is the pioneers in initiating the concept of niche marketing and today, is ranked amongst the leaders in therapeutic segment of cardiovascular (CV), central nervous system (CNS), gastro-intestinal (GI) and women healthcare (WHC). The Company also has significant presence in diabetology, pain management, gynaecology, oncology and anti-infective segments.
REVENUE-MIX BREAK-UP
Torrent’s major pharma markets are India, US, Germany and Brazil
Current Year Fiancial Data
- Market Cap: 40,532 Cr.
- Current Price: 2,395
- 52 weeks High / Low 2699.00 / 1452.00
- Book Value: 285.07
- Stock P/E: 39.54
- Dividend Yield: 0.71 %
- ROCE: 12.66 %
- ROE: 12.75 %
- Sales Growth (3Yrs): 4.69 %
Bonus Share Issue History
Bonus History (Torrent Pharmaceuticals)
| Date | Bonus Ratio |
|---|---|
| 30-05-2013 | 1:1 |
| 15-12-2005 | 1:1 |
Torrent Pharma Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 1,886 | 7,939 | 15.46% |
| Profit | 231 | 1,025 | 16.07% |
| Share Price | 228.15 | 2395 | 26.51% |
#9. Cadila Healthcare Ltd
Cadila Healthcare Ltd is the 9th largest pharma company in India with a market cap of 37,505 Cr. in 2020.
| Industry | Pharmaceuticals |
| Founded | 1951 |
| Founder | Indravadan Modi |
| Chairman | Pankaj Patel |
| MD | Dr. sharvil Patel |
The Zydus Cadila group is one of the top five players in the domestic formulations market. The group is the market leader in the high-growth lifestyle segments such as gastrointestinal, cardiology, respiratory and gynecology, which account for about 40% of its domestic formulation sales
BUSINESS SEGMENTS
US Formulations Business
The US is the largest market for the Company, contributing almost half of
the total revenues. The Company is now ranked seventh amongst US generic companies (based on prescriptions).
India Business
The Company’s formulations business in India, currently the second largest contributor to the consolidated revenues.
The Company is the fourth-largest pharmaceutical company in India with 4.1% market share and is ranked amongst the top three players in the promoted covered market of gynecology, respiratory, pain management, cardiovascular, dermatology and gastrointestinal therapeutic areas.
11 of the Company’s brands feature amongst the top 300 pharmaceutical brands in India with 5 brands having sales of more than Rs.100 crores
(Source: AWACS MAT March 2019).
Consumer Wellness
Zydus Wellness Limited (ZWL), the Company’s subsidiary, drives the Company’s operations in the consumer wellness space, which has a portfolio of leading brands, built organically over the years as well as acquired through an inorganic route.
Animal Health
The Company is one of the leading animal healthcare players in India having a portfolio of drugs, vaccines and feed supplements for livestock, poultry and companion animals
Current Year Fiancial Data
- Market Cap: 37,505 Cr.
- Current Price: 366.35
- 52 weeks High / Low 383.65 / 202.00
- Book Value: 101.35
- Stock P/E: 29.68
- Dividend Yield: 0.96 %
- ROCE: 15.35 %
- ROE: 18.66 %
- Sales Growth (3Yrs): 11.78 %
Bonus Share Issue History
Bonus History (Cadila Healthcare)
| Date | Bonus Ratio |
|---|---|
| 25-02-2010 | 1:2 |
| 28-04-2006 | 1:1 |
Cadila Healthcare Ltd Ltd Performance in last 10 Years
| Year | 2010 | 2020 | CAGR Growth(%) |
| Sales | 3,574 | 14,253 | 14.84% |
| Profit | 505 | 1,177 | 8.83% |
| Share Price | 105.93 | 366.35 | 13.21% |
Note : All Data taken from screener.in
List Of Top 50 Company in India
| S.No. | Name | CMP Rs | P/E | Mar Cap Rs.Cr. | Div. Yld % | ROCE% |
|---|---|---|---|---|---|---|
| 1 | Sun Pharma.Inds. | 476.85 | 28.69 | 114412.3 | 0.63 | 11.19 |
| 2 | Dr Reddy's Labs | 3921.45 | 32.18 | 65187.4 | 0.64 | 12.42 |
| 3 | Divi's Lab. | 2190.45 | 42.24 | 58149.3 | 0.73 | 28.51 |
| 4 | Cipla | 638.8 | 33.3 | 51504.7 | 0.47 | 10.94 |
| 5 | Biocon | 395.6 | 155.83 | 47472.3 | 0.13 | 5.3 |
| 6 | Aurobindo Pharma | 777.85 | 15.99 | 45577.9 | 0.39 | 18.45 |
| 7 | Lupin | 900.05 | 40780.6 | 0.56 | 9.97 | |
| 8 | Torrent Pharma. | 2395.2 | 39.54 | 40531.1 | 0.71 | 12.66 |
| 9 | Cadila Health. | 366.35 | 29.68 | 37504.6 | 0.96 | 15.35 |
| 10 | Abbott India | 15657.45 | 56.11 | 33272.8 | 0.68 | 37.36 |
| 11 | Piramal Enterp. | 1411.05 | 764.65 | 31824.9 | 0.99 | 9.42 |
| 12 | Alkem Lab | 2350.8 | 24.94 | 28107.6 | 1.06 | 16.58 |
| 13 | Glaxosmi. Pharma | 1466.1 | 172.76 | 24836.6 | 1.36 | 32.88 |
| 14 | Ipca Labs. | 1662.7 | 34.65 | 21008. | 0.3 | 16.24 |
| 15 | Pfizer | 4122.85 | 37.05 | 18861.5 | 0.55 | 23.22 |
| 16 | Sanofi India | 7796.15 | 37.59 | 17954.6 | 1.36 | 28.38 |
| 17 | Syngene Intl. | 437.35 | 49.65 | 17494.1 | 0.11 | 16.63 |
| 18 | Alembic Pharma | 897.2 | 19.62 | 16912.8 | 0.78 | 24.25 |
| 19 | Ajanta Pharma | 1409.95 | 26.15 | 12303.2 | 0.92 | 27.61 |
| 20 | Glenmark Pharma. | 432.7 | 16.21 | 12209.6 | 0.46 | 14.78 |
| 21 | Natco Pharma | 663.1 | 26.2 | 12072.2 | 1.02 | 23.33 |
| 22 | Jubilant Life | 683.8 | 11.81 | 10892.3 | 0.73 | 16.37 |
| 23 | Astrazeneca Phar | 3513.65 | 121.63 | 8784.3 | 0.03 | 26.51 |
| 24 | P & G Health Ltd | 4062.5 | 40.99 | 6743.0 | 0 | 78.16 |
| 25 | Suven Pharma | 508.05 | 20.4 | 6466.0 | 0 | |
| 26 | ERIS Lifescience | 447.45 | 20.51 | 6075.4 | 0.64 | 26.43 |
| 27 | J B Chem & Pharm | 718.65 | 19.87 | 5553.9 | 1.39 | 18.36 |
| 28 | Granules India | 209 | 16.85 | 5313.8 | 0.48 | 14.75 |
| 29 | FDC | 266.1 | 18.97 | 4549. | 0.3 | 17.3 |
| 30 | Shilpa Medicare | 471.7 | 24.63 | 3845.3 | 0.23 | 8.74 |
| 31 | Strides Pharma | 413.45 | 30.67 | 3703. | 2.9 | 10.13 |
| 32 | IOL Chemicals | 523 | 8.5 | 3070.7 | 0.57 | 55.53 |
| 33 | Wockhardt | 275.75 | 3053.0 | 0 | -0.56 | |
| 34 | Aarti Drugs | 1277.35 | 22.95 | 2976.6 | 0.16 | 17 |
| 35 | Caplin Point Lab | 339.05 | 11.93 | 2564.5 | 0.65 | 48.53 |
| 36 | Sequent Scien. | 94.65 | 33.62 | 2350.1 | 0.21 | 9.21 |
| 37 | Alembic | 83.4 | 6.51 | 2141.4 | 0.24 | 3.81 |
| 38 | Dishman Carbogen | 126.95 | 11.04 | 1991.6 | 0.16 | 5.72 |
| 39 | Indoco Remedies | 205.3 | 78.43 | 1891.5 | 0.15 | 1.19 |
| 40 | Solara Active | 641.2 | 15.03 | 1721.8 | 0.78 | 10.19 |
| 41 | Hikal | 123.65 | 15.8 | 1524.7 | 0.97 | 15.25 |
| 42 | Marksans Pharma | 34.05 | 11.54 | 1393.5 | 0.15 | 18.51 |
| 43 | Novartis India | 560.45 | 137.28 | 1383.8 | 1.78 | 7.58 |
| 44 | Unichem Labs. | 189.8 | 1336.1 | 2.11 | -2.43 | |
| 45 | Panacea Biotec | 198.15 | 1213.0 | 0 | -13.6 | |
| 46 | Morepen Labs. | 24.15 | 32.35 | 1086.0 | 0 | 8.4 |
| 47 | Amrutanjan Healt | 360.65 | 42.03 | 1054. | 0.6 | 25.42 |
| 48 | Hester Bios | 1210.35 | 35.3 | 1029.1 | 0.91 | 26.65 |
| 49 | Bliss GVS Pharma | 97.35 | 9.82 | 1003.3 | 1.03 | 26.9 |
| 50 | Fermenta Biotec. | 258.25 | 12.99 | 760.5 | 0.65 | 42.01 |
Like!! Really appreciate you sharing this blog post.Really thank you! Keep writing.